Annals of Surgical Oncology

, Volume 25, Issue 12, pp 3476–3482 | Cite as

Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities

  • Hidde M. Kroon
  • Wendy D. van der Bol
  • Katherine T. Tonks
  • Angela  M. Hong
  • George Hruby
  • John F. ThompsonEmail author



When cervical lymph nodes are clinically positive for metastatic melanoma, surgeons may be hesitant to recommend a therapeutic complete lymph node dissection if the patient is elderly or has major comorbidities. A limited local node excision of the clinically positive nodes only, followed by adjuvant radiotherapy to the entire node field, may be an effective alternative in such patients.


All patients who had presented with a primary head and neck melanoma or an unknown primary site and had subsequently undergone limited local node excision and adjuvant radiotherapy for macroscopically involved cervical nodes between 1993 and 2010 at a tertiary referral center were selected for study.


Twenty-eight patients were identified, with a median age of 78 years and a median of 2 major comorbidities. The 5-year regional control, disease-free survival, and overall survival rates were 69%, 44%, and 50%, respectively. At the time of data analysis, seven patients were alive without evidence of disease. Twenty-one patients had died: 11 of melanoma (4 with neck recurrence) and 10 of other causes (2 with neck recurrence).


Excision of clinically positive metastatic cervical lymph nodes followed by radiotherapy provides satisfactory regional disease control without risking serious morbidity or mortality in melanoma patients whose general condition is considered a contraindication for therapeutic complete lymph node dissection.



Funding was provided by Sydney Medical School Foundation.


  1. 1.
    Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472–92.Google Scholar
  2. 2.
    Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AMM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi22–9.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Andersen PS, Chakera AH, Thamsborg AK, Kølle SF, Schmidt G, Klyver H, Drzewiecki KT. Recurrence and survival after neck dissections in cutaneous head and neck melanoma. Dan Med J. 2014;61:A4953.Google Scholar
  4. 4.
    Mack LA, McKinnon JG. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189–99.CrossRefGoogle Scholar
  5. 5.
    Martin RC, Shannon KF, Quinn MJ, et al. The management of cervical lymph nodes in patients with cutaneous melanoma. Ann Surg Oncol. 2012;19:3926–32.CrossRefGoogle Scholar
  6. 6.
    O’Brien CJ, Petersen-Schaefer K, Stevens GN, et al. Adjuvant radiotherapy following neck dissection and parotidectomy for metastatic malignant melanoma. Head Neck. 1997;19:589–94.CrossRefGoogle Scholar
  7. 7.
    Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node filed relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16:1049–60.CrossRefGoogle Scholar
  8. 8.
    Grotz TE, Puig CA, Perkins S, Ballman K, Hieken TJ. Management of regional lymph nodes in the elderly melanoma patient: patient selection, accuracy and prognostic implications. Eur J Surg Oncol. 2015;41:157–64.CrossRefGoogle Scholar
  9. 9.
    Geltzeiler M, Monroe M, Givi B, Vetto J, Andersen P, Gross N. Regional control of head and neck melanoma with selective neck dissection. JAMA Otolaryngol Head Neck Surg. 2014;140:1014–8.CrossRefGoogle Scholar
  10. 10.
    Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013;20:3961–8.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Supriya M, Narasimhan V, Henderson MA, Sizeland A. Managing regional metastasis in patients with cutaneous head and neck melanoma is selective neck dissection appropriate? Am J Otolaryngol. 2014;35:610–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    O’Brien CJ, Petersen-Schaefer K, Ruark D, Coates AS, Menzie SJ, Harrison RI. Radical, modified, and selective neck dissection for cutaneous malignant melanoma. Head Neck. 1995;17:232–41.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hamming-Vrieze O, Balm AJ, Heemsbergen WD, Hooft van Huysduynen T, Rasch CR. Regional control of melanoma neck node metastasis after selective neck dissection with or without adjuvant radiotherapy. Arch Otolaryngol Head Neck Surg. 2009;135:795–800.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mann HB, Whitney DR. On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat. 1947;18:50–60.CrossRefGoogle Scholar
  15. 15.
    Kaplan L, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1985;53:457–81.CrossRefGoogle Scholar
  16. 16.
    Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.CrossRefGoogle Scholar
  17. 17.
    Oxenberg J, Kane JM III. The role of radiation therapy in melanoma. Surg Clin North Am. 2014;94:1031–47.CrossRefGoogle Scholar
  18. 18.
    Van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur J Surg Oncol. 2007;33:102–8.CrossRefGoogle Scholar
  19. 19.
    Feng Z, Gao Y, Niu LX, Peng X, Guo CB. Selective versus comprehensive neck dissection in the treatment of patients with a pathologically node-positive neck with or without microscopic extracapsular spread in oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2014;43:1182–8.CrossRefGoogle Scholar
  20. 20.
    Ballo MT, Garden AS, Myers JN, et al. Melanoma metastatic to cervical lymph nodes: can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005;27:718–21.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol. 2014;15:e371–81.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372:30–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–30.CrossRefGoogle Scholar
  26. 26.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Grünhagen DJ, Kroon HM, Verhoef C. Perfusion and infusion for melanoma in-transit metastases in the era of effective systemic therapy. Am Soc Clin Oncol Educ Book. 2015;35:e528–34.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Hidde M. Kroon
    • 1
  • Wendy D. van der Bol
    • 1
  • Katherine T. Tonks
    • 2
  • Angela  M. Hong
    • 1
    • 3
  • George Hruby
    • 1
    • 3
  • John F. Thompson
    • 1
    • 4
    Email author
  1. 1.Melanoma Institute AustraliaThe University of SydneySydneyAustralia
  2. 2.Garvan Institute of Medical ResearchDarlinghurstAustralia
  3. 3.Department of Radiation OncologyRoyal Prince Alfred HospitalCamperdownAustralia
  4. 4.Department of Melanoma and Surgical OncologyRoyal Prince Alfred HospitalCamperdownAustralia

Personalised recommendations